Keryx Biopharmaceuticals — Q1 2016 Earnings Presentation
23 slides from Keryx Biopharmaceuticals's earnings presentation, Apr 28, 2016
Slide 1: First Quarter 2016 Financial Results
First Quarter 2016 Financial Results April 28, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement the financial measures presented in our press release and related conference call, and in accordance with accounting principles generally accepted in the United States (“GAAP”), Keryx also presents expected cash operating expenses in the 2016 financial guida
Slide 4: First Quarter 2016 Financial Results – Agenda
First Quarter 2016 Financial Results – Agenda Topic Speaker Introduction Amy Sullivan, VP, Corporate Development Strategy, Priorities and Commercial Update Greg Madison, Chief Executive Officer 1Q 2016 Results & Guidance Scott Holmes, Chief Financial Officer IDA NDD-CKD John Neylan, M.D., Chief Medi
Slide 5: Building a Foundation for Long-Term Growth
Building a Foundation for Long-Term Growth SOLID FUNDAMENTALS ESTABLISHED 2015 2017 POTENTIAL IDA APPROVAL 2016 DRIVE DIALYSIS ADOPTION AURYXIA: A NEW TREATMENT CATEGORY Leverage field team expansion Increase utilization Increase breadth & depth of prescribing Generate further data to support differ
Slide 6: First Quarter 2016 Business Highlights
First Quarter 2016 Business Highlights Expanded field based team fully trained and calling on treating community Auryxia net U.S. product sales of $5.6MM Announced positive top-line results from pivotal phase 3 trial for the treatment of iron deficiency anemia in non-dialysis dependent CKD patients
Slide 7: Prescription Volume Increased ~17% from 4Q 2015 to 1Q 2016
Source: IMS NPA, DaVita and Fresenius Prescription Volume Increased ~17% from 4Q 2015 to 1Q 2016 ~9,150 Auryxia prescriptions in 1Q 2016 43% of Auryxia prescriptions in 1Q 2016 not captured by IMS Volume growth driven by increased breadth and depth of prescribing Increased new writers: Cumulative ta
Slide 8: Solid Fundamentals to Support Future Dialysis Growth
Solid Fundamentals to Support Future Dialysis Growth Physician Payer Patient Increased breadth and depth of adoption Expanded field base team fully trained Majority of phosphate binder patients have unrestricted access ~70% of claims paid at the pharmacy ~74% of co-pays <$10 Patient persistency at ~
Slide 9: Financial Highlights
Financial Highlights Scott Holmes Chief Financial Officer
Slide 10: First Quarter 2016 Financial Highlights
First Quarter 2016 Financial Highlights ($ in thousands) Three Months Ended March 31, 2016 (unaudited) Three Months Ended March 31, 2015 (unaudited) Auryxia Net U.S. Product Sales $5,616 $422 License Revenue $1,209 $753 Total Revenue $6,825 $1,175 Cost of Goods Sold $1,071 $76 SG&A Expense $20,809 $
Slide 11: Reconciliation of Total Operating Expenses to Cash Operating Expenses (Non-GAAP)
Reconciliation of Total Operating Expenses to Cash Operating Expenses (Non-GAAP) ($ in thousands) Three Months Ended March 31, 2016 (unaudited) Three Months Ended March 31, 2015 (unaudited) SG&A Expense $20,809 $18,880 R&D Expense $7,616 $9,591 Total Operating Expenses* $28,425 $28,471 Less: non-cas
Slide 12: 2016 Financial Guidance
2016 Financial Guidance $ in millions FY 2016 Guidance Auryxia Net U.S. Product Sales* $31MM - $34MM Cash Operating Expenses $87MM - $92MM* Notes: * 2016 Cash Operating Expenses excludes; non-cash stock compensation expenses, non-cash commercial expenses and non-cash depreciation/amortization
Slide 13: NDD CKD - Iron Deficiency Anemia Label Expansion Opportunity
NDD CKD - Iron Deficiency Anemia Label Expansion Opportunity John Neylan, M.D. Chief Medical Officer
Slide 14: Potential to Treat IDA in NDD-CKD Represents a Practice-Changing Opportunity
Potential to Treat Iron Deficiency Anemia in Non-Dialysis Dependent CKD Represents a Practice-Changing Opportunity Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Na
Slide 15: Progression of Chronic Kidney Disease
Progression of Chronic Kidney Disease Progressing patients typically referred to nephrologist Prepare for renal replacement therapy Patients initiate dialysis GFR (mL/min) Often not diagnosed Patients typically under care of PCP Moderate to severe loss of kidney function Severe loss of kidney functi
Slide 16: Baseline Laboratory Characteristics (ITT Population)
Baseline Laboratory Characteristics (ITT Population) Mean Baseline Laboratory Values Ferric Citrate (N=117) Placebo (N=115) Hemoglobin (g/dL) 10.4 10.4 TSAT (%) 20.2 19.6 Ferritin (ng/mL) 85.9 81.7 Serum phosphorus (mg/dL) 4.2 4.1 Keryx Biopharmaceuticals Announces Positive Top-line Results from Piv
Slide 17: Phase 3 Efficacy Endpoints
*Sustained treatment effect on Hgb was defined as a mean change from baseline ≥0.75 g/dL over any 4-week time period during the 16-week, randomized efficacy period, provided that an increase of at least 1.0 g/dL had occurred during that 4-week period. Randomized Efficacy Period (16 Weeks) Ferric Cit
Slide 18: IDA Phase 3 Top-line Results: Safety
AE Category Ferric Citrate (N=117) % (n) Placebo (N=116) % (n) Most common AEs Diarrhea 20.5 (24) 16.4 (19) Constipation 18.8 (22) 12.9 (15) Discolored feces 14.5 (17) 0 Nausea 11.1 (13) 2.6 (3) SAEs 12.0 (14) 11.2 (13) AEs leading to discontinuation 10.3 (12) 8.6 (10) Death 1.7 (2) 0 The majority o
Slide 19: Ferric Citrate Has Potential to Benefit Many More CKD Patients
Ferric Citrate Has Potential to Benefit Many More Patients with Chronic Kidney Disease Anemia Management Registration Phase 3 study demonstrated statistically significant differences between the ferric citrate and placebo groups for the primary and all pre-specified secondary endpoints Plan to submi
Slide 20: Closing Remarks & Q&A
Closing Remarks & Q&A Greg Madison
Slide 21: A Potential New Treatment Category for CKD
A Potential New Treatment Category for CKD Phosphate Management Anemia Management Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; Ferric citrate is being evaluated for use in non-dialysis dependent CKD patients as a treatment for iron deficiency
Slide 22: Priorities for the Future and Progress Toward Potential Auryxia Label Expansion
Priorities for the Future and Progress Toward Potential Auryxia Label Expansion Drive Auryxia’s path to success in dialysis: Increase awareness Drive breadth and depth of prescribing Finalize Ph 3 IDA NDD-CKD trial and report top-line results Submit sNDA Begin potential IDA/NDD-CKD launch activities
Slide 23: First Quarter 2016 Financial Results
First Quarter 2016 Financial Results April 28, 2016 Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals — Q1 2016 Earnings Presentation on 6ix